IRIS Accounts Production v26.2.0.496 04679847 Board of Directors Board of Directors 1.4.25 31.3.26 31.3.26 true false true false false false true false Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 04679847 2025-03-31 04679847 2026-03-31 04679847 2025-04-01 2026-03-31 04679847 2024-03-31 04679847 2024-04-01 2025-03-31 04679847 2025-03-31 04679847 ns15:EnglandWales 2025-04-01 2026-03-31 04679847 ns14:PoundSterling 2025-04-01 2026-03-31 04679847 ns10:Director1 2025-04-01 2026-03-31 04679847 ns10:Director2 2025-04-01 2026-03-31 04679847 ns10:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 04679847 ns10:SmallEntities 2025-04-01 2026-03-31 04679847 ns10:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 04679847 ns10:SmallCompaniesRegimeForDirectorsReport 2025-04-01 2026-03-31 04679847 ns10:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 04679847 ns10:FullAccounts 2025-04-01 2026-03-31 04679847 1 2025-04-01 2026-03-31 04679847 ns10:OrdinaryShareClass1 2025-04-01 2026-03-31 04679847 ns10:RegisteredOffice 2025-04-01 2026-03-31 04679847 ns5:CurrentFinancialInstruments 2026-03-31 04679847 ns5:CurrentFinancialInstruments 2025-03-31 04679847 ns5:Non-currentFinancialInstruments 2026-03-31 04679847 ns5:Non-currentFinancialInstruments 2025-03-31 04679847 ns5:ShareCapital 2026-03-31 04679847 ns5:ShareCapital 2025-03-31 04679847 ns5:SharePremium 2026-03-31 04679847 ns5:SharePremium 2025-03-31 04679847 ns5:RetainedEarningsAccumulatedLosses 2026-03-31 04679847 ns5:RetainedEarningsAccumulatedLosses 2025-03-31 04679847 ns5:NetGoodwill 2025-04-01 2026-03-31 04679847 ns5:IntangibleAssetsOtherThanGoodwill 2025-04-01 2026-03-31 04679847 ns5:LeaseholdImprovements 2025-04-01 2026-03-31 04679847 ns5:FurnitureFittings 2025-04-01 2026-03-31 04679847 ns5:NetGoodwill 2025-03-31 04679847 ns5:NetGoodwill 2026-03-31 04679847 ns5:NetGoodwill 2025-03-31 04679847 ns5:ShortLeaseholdAssets ns5:LandBuildings 2025-03-31 04679847 ns5:LeaseholdImprovements 2025-03-31 04679847 ns5:FurnitureFittings 2025-03-31 04679847 ns5:ShortLeaseholdAssets ns5:LandBuildings 2025-04-01 2026-03-31 04679847 ns5:ShortLeaseholdAssets ns5:LandBuildings 2026-03-31 04679847 ns5:LeaseholdImprovements 2026-03-31 04679847 ns5:FurnitureFittings 2026-03-31 04679847 ns5:ShortLeaseholdAssets ns5:LandBuildings 2025-03-31 04679847 ns5:LeaseholdImprovements 2025-03-31 04679847 ns5:FurnitureFittings 2025-03-31 04679847 ns5:AdditionsToInvestments 2026-03-31 04679847 ns5:CostValuation 2026-03-31 04679847 ns5:Subsidiary1 2025-04-01 2026-03-31 04679847 1 ns5:Subsidiary1 2025-04-01 2026-03-31 04679847 ns5:Subsidiary1 2026-03-31 04679847 ns5:Subsidiary2 2025-04-01 2026-03-31 04679847 ns5:Subsidiary2 3 2025-04-01 2026-03-31 04679847 ns5:Subsidiary2 2026-03-31 04679847 ns5:Subsidiary3 2025-04-01 2026-03-31 04679847 5 ns5:Subsidiary3 2025-04-01 2026-03-31 04679847 ns5:Subsidiary3 2026-03-31 04679847 ns5:Subsidiary4 2025-04-01 2026-03-31 04679847 ns5:Subsidiary4 7 2025-04-01 2026-03-31 04679847 ns5:Subsidiary4 2026-03-31 04679847 ns5:Subsidiary5 2025-04-01 2026-03-31 04679847 9 ns5:Subsidiary5 2025-04-01 2026-03-31 04679847 ns5:Subsidiary5 2026-03-31 04679847 ns5:Subsidiary6 2025-04-01 2026-03-31 04679847 ns5:Subsidiary6 11 2025-04-01 2026-03-31 04679847 ns5:Subsidiary6 2026-03-31 04679847 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2026-03-31 04679847 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-03-31 04679847 ns5:Non-currentFinancialInstruments ns5:BetweenOneTwoYears 2026-03-31 04679847 ns5:Non-currentFinancialInstruments ns5:BetweenOneTwoYears 2025-03-31 04679847 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2026-03-31 04679847 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2025-03-31 04679847 ns5:MoreThanFiveYears 2026-03-31 04679847 ns5:MoreThanFiveYears 2025-03-31 04679847 ns5:Secured 2026-03-31 04679847 ns5:Secured 2025-03-31 04679847 ns5:DeferredTaxation 2025-03-31 04679847 ns5:DeferredTaxation 2026-03-31 04679847 ns10:OrdinaryShareClass1 2026-03-31 04679847 ns5:RetainedEarningsAccumulatedLosses 2025-03-31 04679847 ns5:SharePremium 2025-03-31 04679847 ns5:RetainedEarningsAccumulatedLosses 2025-04-01 2026-03-31

REGISTERED NUMBER: 04679847 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026

FOR

MATRIX PHARMACY LIMITED

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 4 |

MATRIX PHARMACY LIMITED

COMPANY INFORMATION

FOR THE YEAR ENDED 31 MARCH 2026

| DIRECTORS: | P Hargun

| A Singh

| REGISTERED OFFICE: | 12 Beacon Road

| Walsall

| West Midlands

| WS5 3LF

| REGISTERED NUMBER: | 04679847 (England and Wales)

| ACCOUNTANTS: | Ashcrofts Accountants Limited

| 2 Cedargrove

| Hagley

| Stourbridge

| West Midlands

| DY9 0DR

| BANKERS: | Lloyds Bank plc

| 293 High Street

| West Bromwich

| West Midlands

| B70 8NA

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

BALANCE SHEET

31 MARCH 2026

| 2026 |  | 2025

| Notes | £ | £ |

FIXED ASSETS

Intangible assets | 4 | 1,370,043 |  | 1,509,739 |  |

Tangible assets | 5 | 344,417 |  | 385,986 |  |

Investments | 6 | 600 |  | - |  |

1,715,060 |  | 1,895,725 |  |

CURRENT ASSETS

Stocks | 7 | 461,242 |  | 400,418 |  |

Debtors | 8 | 1,179,120 |  | 1,103,225 |  |

Cash at bank and in hand | 640,868 |  | 414,732 |  |

2,281,230 |  | 1,918,375 |  |

CREDITORS

Amounts falling due within one year | 9 | (1,105,774 | ) | (934,754 | ) |

NET CURRENT ASSETS | 1,175,456 |  | 983,621 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 2,890,516 |  | 2,879,346 |  |

CREDITORS

Amounts falling due after more than one year | 10 | (314,961 | ) | (391,313 | ) |

PROVISIONS FOR LIABILITIES | 14 | (84,594 | ) | (74,717 | ) |

NET ASSETS | 2,490,961 |  | 2,413,316 |  |

CAPITAL AND RESERVES

Called up share capital | 15 | 8 |  | 8 |  |

Share premium | 16 | 1,781,921 |  | 1,781,921 |  |

Retained earnings | 16 | 709,032 |  | 631,387 |  |

SHAREHOLDERS' FUNDS | 2,490,961 |  | 2,413,316 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

BALANCE SHEET - continued

31 MARCH 2026

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 August 2026 and were signed on its behalf by:

A Singh - Director

P Hargun - Director

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

1. | STATUTORY INFORMATION

| Matrix Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Goodwill

| Goodwill, being the amount paid in connection with the acquisition of a business in 2020, is being amortised evenly over its estimated useful life of fifteen years.

| Intangible assets

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Improvements to property | - | Over the term of the lease

| Fixtures, fittings & equipment | - | 20% on reducing balance

| Investments in subsidiaries

| Investments in subsidiary undertakings are recognised at cost.

| Stocks

| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2026

2. | ACCOUNTING POLICIES - continued

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Hire purchase and leasing commitments

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 66 (2025 - 51 ) .

4. | INTANGIBLE FIXED ASSETS

| Goodwill

£ |

| COST

| At 1 April 2025

| and 31 March 2026 | 2,095,447 |  |

| AMORTISATION

| At 1 April 2025 | 585,708 |  |

| Amortisation for year | 139,696 |  |

| At 31 March 2026 | 725,404 |  |

| NET BOOK VALUE

| At 31 March 2026 | 1,370,043 |  |

| At 31 March 2025 | 1,509,739 |  |

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2026

5. | TANGIBLE FIXED ASSETS

| Improvements |  | Fixtures, |

| Short |  | to |  | fittings |

| leasehold |  | property |  | & equipment |  | Totals

£ | £ | £ | £ |

| COST

| At 1 April 2025 | 15,000 |  | 7,241 |  | 750,307 |  | 772,548 |  |

| Additions | - |  | - |  | 39,279 |  | 39,279 |  |

| At 31 March 2026 | 15,000 |  | 7,241 |  | 789,586 |  | 811,827 |  |

| DEPRECIATION

| At 1 April 2025 | 15,000 |  | 1,448 |  | 370,114 |  | 386,562 |  |

| Charge for year | - |  | 145 |  | 80,703 |  | 80,848 |  |

| At 31 March 2026 | 15,000 |  | 1,593 |  | 450,817 |  | 467,410 |  |

| NET BOOK VALUE

| At 31 March 2026 | - |  | 5,648 |  | 338,769 |  | 344,417 |  |

| At 31 March 2025 | - |  | 5,793 |  | 380,193 |  | 385,986 |  |

6. | FIXED ASSET INVESTMENTS

| Shares in

| group

| undertakings

£ |

| COST

| Additions | 600 |  |

| At 31 March 2026 | 600 |  |

| NET BOOK VALUE

| At 31 March 2026 | 600 |  |

| The company's investments at the Balance Sheet date in the share capital of companies include the following:

| Wootton Healthcare Limited

| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF

| Nature of business: Dormant

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

2026 |  |

£ |  |

| Aggregate capital and reserves | 100 |  |

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2026

6. | FIXED ASSET INVESTMENTS - continued

| Tudor Hope Healthcare Limited

| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF

| Nature of business: Dormant

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

2026 |  |

£ |  |

| Aggregate capital and reserves | 100 |  |

| Instore Healthcare Limited

| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF

| Nature of business: Dormant

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

2026 |  |

£ |  |

| Aggregate capital and reserves | 100 |  |

| Thornbury Healthcare Limited

| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF

| Nature of business: Dormant

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

2026 |  |

£ |  |

| Aggregate capital and reserves | 100 |  |

| Areley Healthcare Limited

| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF

| Nature of business: Dormant

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

2026 |  |

£ |  |

| Aggregate capital and reserves | 100 |  |

| Alveston Healthcare Limited

| Registered office: 12 Beacon Road, Walsall, West Midlands, WS5 3LF

| Nature of business: Dormant

| %

| Class of shares: | holding |

| Ordinary | 100.00 |

2026 |  |

£ |  |

| Aggregate capital and reserves | 100 |  |

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2026

7. | STOCKS

2026 | 2025 |

£ | £ |

| Stocks | 461,242 |  | 400,418 |  |

8. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2026 | 2025 |

£ | £ |

| Trade debtors | 653,524 |  | 587,163 |  |

| Amounts owed by group undertakings | 379,233 |  | 268,153 |  |

| Other debtors | 9,000 |  | 9,000 |  |

| VAT | 90,314 |  | 147,379 |  |

| Prepayments and accrued income | 47,049 |  | 91,530 |  |

1,179,120 |  | 1,103,225 |  |

9. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2026 | 2025 |

£ | £ |

| Bank loans and overdrafts (see note 11) | 71,095 |  | 61,500 |  |

| Trade creditors | 745,500 |  | 793,711 |  |

| Amounts owed to group undertakings | 600 |  | - |  |

| Corporation tax | 104,917 |  | - |  |

| Social security and other taxes | 19,354 |  | 14,539 |  |

| Other creditors | 156,548 |  | 57,620 |  |

| Accruals and deferred income | 7,760 |  | 7,384 |  |

1,105,774 |  | 934,754 |  |

10. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

2026 | 2025 |

£ | £ |

| Bank loans (see note 11) | 314,961 |  | 391,313 |  |

| Amounts falling due in more than five years:

| Repayable by instalments

| Bank loans more 5 yr by instal | 18,582 |  | 99,113 |  |

11. | LOANS

| An analysis of the maturity of loans is given below:

2026 | 2025 |

£ | £ |

| Amounts falling due within one year or on demand:

| Bank loans | 71,095 |  | 61,500 |  |

| Amounts falling due between one and two years:

| Bank loans - 1-2 years | 72,295 |  | 62,700 |  |

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2026

11. | LOANS - continued

2026 | 2025 |

£ | £ |

| Amounts falling due between two and five years:

| Bank loans - 2-5 years | 224,084 |  | 229,500 |  |

| Amounts falling due in more than five years:

| Repayable by instalments

| Bank loans more 5 yr by instal | 18,582 |  | 99,113 |  |

12. | LEASING AGREEMENTS

| Minimum lease payments under non-cancellable operating leases fall due as follows:

2026 | 2025 |

£ | £ |

| In more than five years | 135,300 |  | 132,300 |  |

13. | SECURED DEBTS

| The following secured debts are included within creditors:

2026 | 2025 |

£ | £ |

| Bank loans | 386,056 |  | 452,813 |  |

14. | PROVISIONS FOR LIABILITIES

2026 | 2025 |

£ | £ |

| Deferred tax | 84,594 |  | 74,717 |  |

| Deferred |

| tax |

£ |

| Balance at 1 April 2025 | 74,717 |  |

| Charged during the year | 9,877 |  |

| Balance at 31 March 2026 | 84,594 |  |

15. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2026 | 2025 |

| value: | £ | £ |

| 8 | Ordinary | £1 | 8 |  | 8 |  |

MATRIX PHARMACY LIMITED (REGISTERED NUMBER: 04679847)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2026

16. | RESERVES

| Retained |  | Share |

| earnings |  | premium |  | Totals

£ | £ | £ |

| At 1 April 2025 | 631,387 |  | 1,781,921 |  | 2,413,308 |  |

| Profit for the year | 204,645 |  | 204,645 |  |

| Dividends | (127,000 | ) | (127,000 | ) |

| At 31 March 2026 | 709,032 |  | 1,781,921 |  | 2,490,953 |  |

17. | RELATED PARTY DISCLOSURES

| At 31 March 2026, there was a loan from Matrix Primary Healthcare Limited of £156,548 (2025: £57,421), a company in which Mr P Hargun and Mr A Singh are directors. This unsecured loan is interest free and repayable on demand.

| At 31 March 2026, there was a loan to Matrix Asset Holdings Limited of £379,233 (2025: £268,153), a company in which Mr P Hargun and Mr A Singh are directors. Matrix Asset Holdings Limited is the parent undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand.

| At 31 March 2026, there was a loan from Wootton Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Wootton Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand.

| At 31 March 2026, there was a loan from Tudor Hope Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Tudor Hope Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand.

| At 31 March 2026, there was a loan from Instore Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Instore Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand.

| At 31 March 2026, there was a loan from Thornbury Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Thornbury Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand.

| At 31 March 2026, there was a loan from Areley Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Areley Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand.

| At 31 March 2026, there was a loan from Alveston Healthcare Limited of £100 (2025: £Nil), a company in which Mr P Hargun and Mr A Singh are directors. Alveston Healthcare Limited is a subsidiary undertaking of Matrix Pharmacy Limited. This unsecured loan is interest free and repayable on demand.

18. | ULTIMATE CONTROLLING PARTY

| The controlling party is Matrix Asset Holdings Limited.